Revolutionizing Drug Discovery: The Power of Life-Like Brain Wiring Models
The quest for effective treatments for multiple sclerosis (MS) and other degenerative brain diseases has received a significant boost with the development of a groundbreaking brain wiring model. This innovative model, created by researchers at University College London (UCL), offers a more realistic representation of microscopic nerve fibers, known as axons, which could revolutionize the drug discovery process.
In a recent study, the research team introduced a novel physical model made of tiny pillars, each tens of times thinner than a human hair, that replicate the structure of axons. What sets this model apart is its composition of a water-filled gel (hydrogel), which provides a soft and flexible environment, closely mimicking the physical properties of real-life axons.
The study's findings are particularly intriguing. By growing myelin from human and animal cells around these pillars and testing drugs designed to restore or repair damaged myelin, the researchers discovered that the drugs' performance varied significantly depending on the model's realism. When the model axons were made softer, resembling real-life axons, the drugs' effectiveness diminished.
This revelation is crucial because it highlights a potential reason for the failure of past drugs in human trials. The traditional rigid models, which are hundreds of times stiffer than actual axons, may have yielded promising results in the lab but failed to translate those findings into successful treatments in humans. The discrepancy between the lab and real-world outcomes can be attributed to the lack of physical realism in these models.
Professor Emad Moeendarbary, a senior author of the study from UCL Mechanical Engineering, emphasizes the importance of this breakthrough. He suggests that the commonly used rigid models can lead to misleading drug candidates, and the new, more life-like model can serve as a robust early test platform for drug discovery. By replicating the basic physical properties of the human brain, this model provides a more accurate assessment of drug efficacy.
Furthermore, the study marks a significant milestone by successfully growing myelin from human cells in the laboratory for the first time. This achievement opens up new avenues for research, allowing scientists to explore the intricate relationship between brain wiring and disease progression.
In conclusion, this groundbreaking brain wiring model has the potential to transform drug discovery for MS and other degenerative brain diseases. By providing a more realistic representation of the human brain, it offers a promising avenue for developing effective therapies. As the research community continues to refine and expand upon this model, we can anticipate significant advancements in our understanding and treatment of these complex neurological conditions.
